SCHEMBL7149130

SCHEMBL7149130

COc1ccc2nc(SCCS(=O)(=O)Nc3ccccc3OC)sc2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.53
KMT2A Q03164 6/20 0.53
MEN1 O00255 5/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53
NFKB1 P19838 1/20 0.53
GFER P55789 1/20 0.53
NFKB2 Q00653 1/20 0.53
RELA Q04206 1/20 0.53
LMNA P02545 4/20 0.50
MAPK1 P28482 3/20 0.50
HTT P42858 2/20 0.50
PDK1 Q15118 1/20 0.48
ALDH1A1 P00352 4/20 0.46
HSD17B10 Q99714 1/20 0.46
CSNK1D P48730 1/20 0.45
POLB P06746 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
PTK2B Q14289 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7151765 0.94 MAPT (0.52) MAPTKMT2AMEN1SMN1; SMN2NPC1
SCHEMBL7149243 0.93 MAPT (0.51) MAPTKMT2AMEN1SMN1; SMN2NPC1
SCHEMBL7154156 0.90 MAPT (0.48) MAPTKMT2AMEN1SMN1; SMN2NPC1
SCHEMBL7153200 0.90 MAPT (0.55) MAPTKMT2AMEN1SMN1; SMN2NPC1
SCHEMBL7149622 0.89 ALDH1A1 (0.59) MAPTKMT2AMEN1SMN1; SMN2LMNA
SCHEMBL7151273 0.86 MAPT (0.52) MAPTKMT2AMEN1SMN1; SMN2NPC1
SCHEMBL7153222 0.85 PDK1 (0.53) MAPTKMT2AMEN1SMN1; SMN2NPC1
SCHEMBL7152196 0.85 MAPT (0.49) MAPTKMT2AMEN1SMN1; SMN2NPC1
SCHEMBL7152177 0.84 ALDH1A1 (0.46) MAPTKMT2AMEN1SMN1; SMN2NPC1
SCHEMBL7151731 0.84 MAPT (0.48) MAPTKMT2AMEN1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6642263-B2 Antitumor agents, sulfided benzothiazole derivative containing sulfonamide ICONIX PHARMACEUTICALS INC. 2003-11-04 US disclosed
US-20030176474-A1 Modulators of Rho C activity ICONIX BIOSCIENCES, INC. 2003-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176474-A1 Modulators of Rho C activity RHOC, ARHGDIA, ROCK1 MAPT 3839/4885KMT2A 4174/4885MEN1 4162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.